Core Viewpoint - Ipsen has received regulatory approval from Japan's Ministry of Health, Labour and Welfare for Bylvay (odevixibat) to treat pruritus associated with progressive familial intrahepatic cholestasis (PFIC), a rare genetic disorder that leads to severe itching and liver damage [1][2][3] Company Overview - Ipsen is a global biopharmaceutical company focused on developing transformative medicines in oncology, rare diseases, and neuroscience, with nearly 100 years of development experience [10] - The company is listed on Euronext in Paris and has a Sponsored Level I American Depositary Receipt program in the U.S. [11] Product Information - Bylvay is a once-daily oral ileal bile acid transport inhibitor (IBATi) that reduces bile acid reabsorption, showing significant improvements in serum bile acid levels and pruritus severity in clinical trials [2][5] - The drug was previously approved in the EU and the U.S. for various age groups and conditions related to PFIC and cholestatic pruritus [5][6] Clinical Trial Insights - The approval in Japan was based on a Phase III open-label study that confirmed the efficacy and safety of odevixibat in pediatric patients with PFIC types 1 and 2, consistent with global trial results [3][9] - The PEDFIC trial, the largest global Phase III trial for PFIC, demonstrated that 55% of patients on odevixibat achieved a reduction in pruritus compared to 30% on placebo, and 33% showed a significant reduction in serum bile acid levels [7][13] Market Impact - PFIC affects an estimated 100 children and infants in Japan, highlighting the need for effective treatment options [6] - The approval of Bylvay provides a non-surgical treatment alternative for patients suffering from this debilitating condition, potentially improving their quality of life [2][3]